Notifications

Home

Stocks
- Stock Screener
- Market Movers
- Insider Trades
- Upcoming Earnings
- Upcoming Dividends
Options
- Unusual Options Activity
- Implied Volatility Rank
- Volatility %Change
News
Upcoming IPOs

Arcus Biosciences Inc (RCUS)

$8.47 -0.12 (-1.40%)

Overview
Financial
Short Interest
Institutional Holdings
Dividends
Charts

Market Cap	896.85M
Revenue (ttm)	258.00M
Net Income (ttm)	-283.00M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-109.69%
Debt to Equity Ratio	0.09

Volume	297,200
Avg Vol	1,206,748
Day's Range	N/A - N/A
Shares Out	105.89M
Stochastic %K	58%
Beta	0.80
Analysts	Strong Sell
Price Target	$28.18

Company Profile

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; and Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway...

Industry: Biotechnology

Sector: Healthcare

Phone: 510 694 6200

Website: www.arcusbio.com

Address:

3928 Point Eden Way, Hayward, United States

TabJones24 Jul. 7 at 10:10 AM

$RCUS Should open around 2 Based on what I'm hearing

0 · Reply

TabJones24 Jul. 5 at 6:17 PM

$RCUS When does Trump deport higher ups

0 · Reply

forprofit12 Jul. 2 at 8:50 PM

$RCUS pinned down to expire the July contracts otm?

0 · Reply

TabJones24 Jul. 1 at 7:53 PM

$RCUS Look at AUPH And see your destiny

2 · Reply

FFidelio23 Jul. 1 at 3:01 PM

$RCUS someone ring bell time to close up shop here

0 · Reply

TabJones24 Jul. 1 at 1:27 PM

$RCUS Something wrong here Its obvious

0 · Reply

TabJones24 Jun. 30 at 9:21 PM

$RCUS It over

1 · Reply

NiceBuzz Jun. 29 at 3:10 AM

$RCUS might buy some monday, but $SNDX has more potential

0 · Reply

Bobes Jun. 27 at 10:52 PM

$RCUS f me today

1 · Reply

MRTunity Jun. 27 at 10:11 PM

$TGTX same shit across the board! Look at $SLS and $RCAT or $RCUS - a lot of rebalancing in the Russell and index’s AH !

4 · Reply

Arcus Biosciences Announces New Employment Inducement Grants

Jun 1, 2025, 10:45 AM EDT - 5 weeks ago

Initial Data from the ARC-20 Study of Casdatifan Plus Cabozantinib Showed Nearly Half of Patients with Metastatic Kidney Cancer Had a Confirmed Response

May 6, 2025, 8:17 PM EDT - 2 months ago

Arcus Biosciences, Inc. (RCUS) Q1 2025 Earnings Call Transcript

May 6, 2025, 4:05 PM EDT - 2 months ago

Arcus Biosciences Reports First-Quarter 2025 Financial Results and Provides a Pipeline Update

Apr 23, 2025, 4:05 PM EDT - 2 months ago

Arcus Biosciences to Present First Combination Data for HIF-2a Inhibitor Casdatifan Plus Cabozantinib in an Oral Presentation at the 2025 ASCO Annual Meeting

Apr 22, 2025, 4:05 PM EDT - 2 months ago

Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2025 Financial Results and Pipeline Update

Apr 2, 2025, 3:48 PM EDT - 3 months ago

Arcus Biosciences: A High-Risk Speculation With Multiple Large, Near-Term Catalysts

Feb 26, 2025, 4:35 PM EST - 4 months ago

Arcus Biosciences to Participate in Two Upcoming Investor Conferences

Feb 25, 2025, 4:05 PM EST - 4 months ago

Arcus Biosciences Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides a Pipeline Update

Feb 18, 2025, 6:57 AM EST - 4 months ago

Arcus Biosciences Retains Rights to Casdatifan, a Potential Best-in-Class HIF-2a Inhibitor, and Announces Pricing of $150 Million Common Stock Offering

Feb 18, 2025, 6:52 AM EST - 4 months ago

Arcus Biosciences, Inc. Announces Underwritten Offering of Common Stock

Feb 15, 2025, 3:45 PM EST - 5 months ago

New Data Demonstrated Best-in-Class Potential for Casdatifan, a HIF-2a Inhibitor, in Patients with Metastatic Kidney Cancer

Feb 10, 2025, 5:00 PM EST - 5 months ago

Arcus Biosciences to Present New Data from Casdatifan, a HIF-2a Inhibitor, in an Oral Presentation at the 2025 ASCO GU Symposium

Jan 21, 2025, 4:05 PM EST - 5 months ago

Arcus Biosciences Appoints Richard Markus, M.D., Ph.D. as Chief Medical Officer

Jan 14, 2025, 10:51 PM EST - 6 months ago

Arcus Biosciences: Many Important Oncology Catalysts Coming Up In 2025

Jan 13, 2025, 8:00 AM EST - 6 months ago

Arcus: Excellent Pipeline And Collaborations, Cash Runway

Dec 19, 2024, 4:05 PM EST - 7 months ago

Arcus Biosciences to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Nov 6, 2024, 11:39 PM EST - 8 months ago

Arcus Biosciences, Inc. (RCUS) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 4:22 PM EST - 8 months ago

Arcus Biosciences Reports Third-Quarter 2024 Financial Results and Provides a Pipeline Update

Nov 5, 2024, 9:00 AM EST - 8 months ago

Arcus Biosciences Announces that Domvanalimab Plus Zimberelimab Improved Overall Survival in ARC-10, a Randomized Study in Patients with PD-L1-High Non-Small Cell Lung Cancer

Oct 30, 2024, 9:00 AM EDT - 8 months ago

Arcus Biosciences to Present New Data for Anti-TIGIT Domvanalimab Plus Zimberelimab at the Society for Immunotherapy of Cancer Annual Meeting

Oct 24, 2024, 7:30 AM EDT - 9 months ago

First Clinical Data for Arcus Biosciences' HIF-2a Inhibitor, Casdatifan, Showed Promising Clinical Activity and Tumor Shrinkage in Patients with Metastatic Kidney Cancer

Oct 22, 2024, 4:05 PM EDT - 9 months ago

Arcus Biosciences to Host Conference Call to Discuss Third-Quarter 2024 Financial Results and Pipeline Update

Oct 9, 2024, 8:00 AM EDT - 9 months ago

Arcus Biosciences to Present First Clinical Data from ARC-20 Study at the 2024 EORTC-NCI-AACR Symposium

Oct 2, 2024, 4:05 PM EDT - 9 months ago

Arcus Biosciences Announces Clinical Trial Collaboration Agreement to Evaluate Casdatifan in Combination with Volrustomig in Renal Cell Carcinoma

AZN

Sep 23, 2024, 1:53 AM EDT - 10 months ago

Arcus Biosciences Looks Compelling Ahead Of Key Clinical Oncology Milestones

Aug 27, 2024, 4:05 PM EDT - 11 months ago

Arcus Biosciences Secures Up to $250 Million Term Loan Facility from Hercules Capital

HTGC

Aug 9, 2024, 5:31 PM EDT - 11 months ago

Arcus Biosciences: Getting Too Cheap To Ignore (Reiterate Buy)

Aug 9, 2024, 5:21 PM EDT - 11 months ago

Arcus Biosciences, Inc. (RCUS) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 4:05 PM EDT - 11 months ago

Arcus Biosciences Reports Second-Quarter 2024 Financial Results and Provides a Pipeline Update

Jul 25, 2024, 4:05 PM EDT - 1 year ago

Arcus Biosciences to Host Conference Call to Discuss Second-Quarter 2024 Financial Results and Pipeline Update

Jul 8, 2024, 6:00 PM EDT - 1 year ago

Taiho Pharmaceutical Exercises Option for an Exclusive License to Quemliclustat in Japan and Certain Territories in Asia

Jun 10, 2024, 8:30 AM EDT - 1 year ago

Arcus Biosciences Completes Patient Enrollment in Phase 3 Trial Evaluating a Domvanalimab-Containing Regimen in First-Line Metastatic Upper GI Cancers

Jun 6, 2024, 4:05 PM EDT - 1 year ago

Arcus Biosciences to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Jun 2, 2024, 8:00 AM EDT - 1 year ago

Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer

GILD

Jun 1, 2024, 8:00 AM EDT - 1 year ago

Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers

GILD

May 8, 2024, 9:55 PM EDT - 1 year ago

Arcus Biosciences, Inc. (RCUS) Q1 2024 Earnings Call Transcript

May 8, 2024, 4:02 PM EDT - 1 year ago

Arcus Biosciences Reports First-Quarter 2024 Financial Results and Provides a Pipeline Update

May 2, 2024, 4:05 PM EDT - 1 year ago

Arcus Biosciences to Participate in the Bank of America Healthcare Conference 2024

Apr 24, 2024, 4:00 PM EDT - 1 year ago

Arcus Biosciences to Present New Data from Phase 2 Studies of Novel Immuno-Oncology Combinations at the 2024 ASCO Annual Meeting

Apr 23, 2024, 4:05 PM EDT - 1 year ago

Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2024 Financial Results and Pipeline Update

Feb 22, 2024, 2:08 AM EST - 1 year ago

Arcus Biosciences, Inc. (RCUS) Q4 2023 Earnings Call Transcript

Feb 21, 2024, 4:05 PM EST - 1 year ago

Arcus Biosciences Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides a Pipeline Update

Feb 7, 2024, 5:00 PM EST - 1 year ago

Arcus Biosciences to Host Conference Call to Discuss Fourth-Quarter and Full-Year 2023 Financial Results and Pipeline Updates

Jan 29, 2024, 6:20 PM EST - 1 year ago

Gilead Sciences raises stake in cancer-centric Arcus Biosciences to 33%

GILD

Jan 29, 2024, 5:00 PM EST - 1 year ago

Gilead and Arcus Announce Amended Collaboration and Equity Investment

GILD

Jan 16, 2024, 5:00 PM EST - 1 year ago

Data from a Phase 1b Study of Quemliclustat-Based Regimens Showed Promising Overall Survival in Treatment-Naïve Metastatic Pancreatic Cancer

Jan 10, 2024, 8:01 AM EST - 1 year ago

iTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must Watch

AGEN BMY CGEN GSK ITOS MRK NVS

Dec 26, 2023, 12:18 PM EST - 1 year ago

20 favorite small-cap stocks for 2024 among Wall Street analysts

ARLO CPRX DGII DVAX GPRE HLX IRWD

Dec 15, 2023, 2:25 AM EST - 1 year ago

Arcus Biosciences: Showing There Might Be Something To TIGIT After All

TabJones24 Jul. 7 at 10:10 AM

$RCUS Should open around 2 Based on what I'm hearing

0 · Reply

TabJones24 Jul. 5 at 6:17 PM

$RCUS When does Trump deport higher ups

0 · Reply

forprofit12 Jul. 2 at 8:50 PM

$RCUS pinned down to expire the July contracts otm?

0 · Reply

TabJones24 Jul. 1 at 7:53 PM

$RCUS Look at AUPH And see your destiny

2 · Reply

FFidelio23 Jul. 1 at 3:01 PM

$RCUS someone ring bell time to close up shop here

0 · Reply

TabJones24 Jul. 1 at 1:27 PM

$RCUS Something wrong here Its obvious

0 · Reply

TabJones24 Jun. 30 at 9:21 PM

$RCUS It over

1 · Reply

NiceBuzz Jun. 29 at 3:10 AM

$RCUS might buy some monday, but $SNDX has more potential

0 · Reply

Bobes Jun. 27 at 10:52 PM

$RCUS f me today

1 · Reply

MRTunity Jun. 27 at 10:11 PM

$TGTX same shit across the board! Look at $SLS and $RCAT or $RCUS - a lot of rebalancing in the Russell and index’s AH !

4 · Reply

tradingjunk321 Jun. 27 at 9:13 PM

$RCUS index rebalancing!

0 · Reply

Family_Guy_ Jun. 27 at 8:10 PM

$RCUS trying to verify if my app is glitching

1 · Reply

forprofit12 Jun. 27 at 8:10 PM

$RCUS I was going to say the same thing. I think volume around 3:20 pm was 300k and now 3.3 million. What happened at the close?

0 · Reply

Family_Guy_ Jun. 27 at 8:03 PM

$RCUS does anyone else see the volume at the end? That was unusual today wasnt a major opex day.

0 · Reply

Bobes Jun. 27 at 7:58 PM

$RCUS wow i guess cas not worth anything and dom failed.

1 · Reply

BIgkill Jun. 27 at 7:13 PM

$RCUS

0 · Reply

Randy2979 Jun. 27 at 6:33 PM

$RCUS RIP !

1 · Reply

Randy2979 Jun. 26 at 2:36 PM

$RCUS https://www.biospace.com/business/tigit-turmoil-how-pharma-burned-billions-on-failed-immuno-oncology-projects

1 · Reply

ACES_ Jun. 26 at 2:01 PM

$RCUS 6 k shares.. seriously?

0 · Reply

Bobes Jun. 26 at 12:00 PM

$RCUS just dont get the valuation here. Multiple p3 trials with real potential of hitting especially Cas and the company is valued below cash. This will correct at somepoint

2 · Reply

TheGunnerAB Jun. 25 at 11:27 PM

$RCUS Short Interest down 1M shares.

0 · Reply

TheGunnerAB Jun. 25 at 6:32 PM

$RCUS i didn't abandon any ship. There is nothing to post. I guess it all depends on your time horizon.

1 · Reply

1.0.0